Saxenda (Liraglutide): The Daily-Injection GLP-1 That Started It All
Saxenda is liraglutide — a daily GLP-1 injection, FDA-approved for weight loss in 2014. It produces about 5–10% weight loss on average, less than semaglutide or tirzepatide. It is sometimes the only covered option, and is approved down to age 12 for adolescents with obesity.
Saxenda was the first GLP-1 approved for chronic weight management, and for almost a decade it was the only one. It has been overshadowed by semaglutide and tirzepatide, but it still has a role.
What it is
Saxenda is liraglutide — a daily-injection GLP-1 receptor agonist. The same molecule at a lower dose is sold under the brand name Victoza for type 2 diabetes. Manufactured by Novo Nordisk.
Dose
Liraglutide titrates over 5 weeks:
- Week 1: 0.6 mg/day
- Week 2: 1.2 mg/day
- Week 3: 1.8 mg/day
- Week 4: 2.4 mg/day
- Week 5+: 3.0 mg/day (maintenance)
Yes — daily. This is the biggest practical drawback compared to weekly semaglutide and tirzepatide.
Effectiveness
In the SCALE trials, average weight loss at 56 weeks on liraglutide 3.0 mg was about 8% of body weight, vs ~15% for semaglutide and ~21% for tirzepatide at their highest doses. About a third of liraglutide patients lost ≥10% of body weight, vs more than two-thirds of tirzepatide patients.
When Saxenda still makes sense
Despite being less powerful, Saxenda has niches:
- Insurance only covers Saxenda. Some plans still favor the older drug.
- Pediatric use. Saxenda is FDA-approved for adolescents (age 12+) with obesity. Wegovy is also approved here, but the longer track record on liraglutide gives some prescribers more comfort.
- Patients who can't tolerate stronger GLP-1s. A patient who has severe side effects on Wegovy or Mounjaro may tolerate Saxenda's gentler appetite suppression.
- Daily dosing as a feature. Some patients prefer daily because they want shorter half-life if they need to stop quickly (e.g., before surgery).
Side effects
Same family as other GLP-1s:
- Nausea (very common, especially in first month)
- Constipation or diarrhea
- Headache
- Hypoglycemia in diabetics on insulin
- Injection site reactions
- Rare: pancreatitis, gallbladder disease, kidney issues
The shorter half-life means side effects ramp up and resolve faster than with weekly drugs.
The protein and muscle problem applies here too
Less weight loss does not mean less muscle loss risk. The protein floor and resistance-training requirements are the same — and arguably more important if you're losing weight slowly, because there's more time across which lean mass erosion can compound unnoticed.
Bottom line
Saxenda is the older, daily, less-powerful GLP-1. If your insurance covers it, it works. If you have a choice between Saxenda and a weekly drug at the same out-of-pocket cost, the weekly drug is almost always the better fit. The same protein and lifting protocol applies regardless of which GLP-1 you're on.